Cancer Nuclear Medicine Diagnostics Market 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Cancer Nuclear Medicine Diagnostics Market Outlook

As per our latest research, the global cancer nuclear medicine diagnostics market size in 2025 stands at USD 7.55 billion, with a robust compound annual growth rate (CAGR) of 10.7% expected from 2026 to 2034. By 2034, the market is forecasted to reach USD 20.87 billion. The primary growth driver for this market is the increasing prevalence of various cancer types worldwide, coupled with rising awareness and adoption of advanced diagnostic modalities that leverage nuclear medicine for early and precise cancer detection.

Get Free Sample Report

One of the most significant growth factors for the cancer nuclear medicine diagnostics market is the rapid advancement in radiopharmaceutical development. The introduction of novel SPECT and PET radiopharmaceuticals has revolutionized the ability of clinicians to detect and stage cancers at earlier phases, which is critical for improving patient outcomes. The ongoing research and development activities, supported by both public and private investment, have resulted in more targeted and effective diagnostic agents. Furthermore, the growing body of clinical evidence supporting the superiority of nuclear medicine imaging over traditional diagnostic methods, especially in terms of sensitivity and specificity, is further propelling the adoption of these technologies across the globe in 2025 and beyond.

Another crucial driver is the increasing burden of cancer worldwide. According to the World Health Organization, cancer remains one of the leading causes of morbidity and mortality, with millions of new cases diagnosed annually. This surge in cancer incidence is pushing healthcare systems to adopt more efficient and accurate diagnostic tools. Nuclear medicine diagnostics, such as PET and SPECT scans, provide functional imaging that enables the early detection of malignancies, assessment of treatment response, and monitoring of disease progression. Additionally, the integration of nuclear medicine with advanced imaging modalities like CT and MRI is enhancing diagnostic accuracy, which is further fueling market growth. The broader landscape of cancer diagnostics continues to evolve rapidly, with nuclear imaging claiming an increasingly central role.

The expanding healthcare infrastructure, particularly in emerging economies, is also playing a pivotal role in the growth of the cancer nuclear medicine diagnostics market. Governments and private healthcare providers are investing heavily in modernizing diagnostic facilities and making advanced nuclear medicine technologies more accessible to a larger population base. Moreover, favorable reimbursement policies in developed countries, coupled with increasing awareness among patients and healthcare professionals about the benefits of nuclear medicine diagnostics, are encouraging higher adoption rates. The rising demand for non-invasive diagnostic procedures, which offer rapid and accurate results, is another factor contributing to market expansion.

From a regional perspective, North America currently dominates the global cancer nuclear medicine diagnostics market, accounting for the largest revenue share in 2025. This is attributed to the presence of a well-established healthcare system, high adoption rates of advanced diagnostic technologies, and significant investments in research and development. Europe follows closely, driven by supportive government initiatives and a strong focus on cancer screening programs. The Asia Pacific region is anticipated to exhibit the highest growth rate over the 2026-2034 forecast period, owing to increasing healthcare expenditure, rising cancer incidence, and growing awareness about the advantages of nuclear medicine diagnostics. Latin America and the Middle East and Africa are also witnessing gradual growth, primarily due to improving healthcare infrastructure and increasing access to advanced diagnostic services.

Product Type Analysis

The cancer nuclear medicine diagnostics market by product type is segmented into SPECT radiopharmaceuticals, PET radiopharmaceuticals, and planar scintigraphy. SPECT radiopharmaceuticals hold a significant share of the market in 2025, owing to their widespread clinical use and cost-effectiveness compared to other modalities. SPECT imaging provides valuable functional information about tumors, enabling clinicians to differentiate between benign and malignant lesions. The continuous development of new SPECT tracers targeting specific tumor markers is enhancing diagnostic precision, which is driving the growth of this segment. Additionally, the availability of SPECT cameras in a majority of hospitals and diagnostic centers, along with favorable reimbursement policies, is further fueling the demand for SPECT radiopharmaceuticals. The expanding field of radiopharmaceutical diagnostics is introducing next-generation SPECT agents that offer improved target specificity and lower radiation doses.

Get Free Sample Report

PET radiopharmaceuticals represent the fastest-growing and now the leading segment within the product type category, commanding approximately 46.8% of total market revenue in 2025. The increasing utilization of PET imaging in oncology is attributed to its superior sensitivity and ability to provide quantitative information about tumor metabolism. The introduction of novel PET tracers, such as those targeting prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAP), and other cancer-specific biomarkers, is expanding the scope of PET imaging well beyond traditional fluorodeoxyglucose (FDG) applications. The growing adoption of hybrid imaging systems, such as PET/CT and PET/MRI, is also contributing to the rising demand for PET radiopharmaceuticals. These advanced systems offer comprehensive anatomical and functional information, enabling more accurate diagnosis and treatment planning. Regulatory approvals granted in 2023 and 2024 for several PSMA-targeted and somatostatin receptor-targeted tracers continue to shape the competitive dynamics of this segment heading into the 2026-2034 forecast window.

Planar scintigraphy, while less commonly used compared to SPECT and PET, still plays a role in certain cancer diagnostic applications. This modality is particularly useful in resource-limited settings where access to advanced imaging technologies may be restricted. Planar scintigraphy provides valuable information about the distribution of radiotracers in the body, which can aid in the detection of metastatic disease and assessment of organ function. However, the lower spatial resolution and limited anatomical detail compared to SPECT and PET have led to a gradual decline in the use of planar scintigraphy for cancer diagnostics. Nevertheless, ongoing efforts to improve image quality and develop new radiotracers may help sustain demand in specific clinical scenarios such as bone scintigraphy and thyroid cancer follow-up.

The competitive landscape within the product type segment is characterized by continuous innovation and strategic collaborations among key market players. Companies are investing in the development of next-generation radiopharmaceuticals with improved targeting capabilities and reduced side effects. Regulatory approvals of new products and the expansion of manufacturing capacities are also contributing to market growth. Furthermore, partnerships between pharmaceutical companies, research institutions, and medical device manufacturers are facilitating the translation of innovative radiopharmaceuticals from the laboratory to clinical practice, thereby driving the overall expansion of the cancer nuclear medicine diagnostics market. The convergence of theranostics, where the same molecular target is used for both diagnosis and therapy, is emerging as a particularly powerful commercial and clinical opportunity within this product segment.

Report Scope

Application Analysis

The application segment of the cancer nuclear medicine diagnostics market is broadly categorized into oncology, cardiology, neurology, thyroid, and others. Oncology remains the dominant application area, accounting for the largest share of the market in 2025. The high prevalence of various cancers, coupled with the critical need for early detection and accurate staging, is driving the demand for nuclear medicine diagnostics in oncology. PET and SPECT imaging have become essential tools in the management of cancer patients, enabling clinicians to assess tumor metabolism, monitor response to therapy, and detect recurrence. The continuous development of new radiotracers targeting specific cancer types, including lung, breast, prostate, colorectal, and neuroendocrine tumors, is further enhancing the utility of nuclear medicine in oncology. Demand from this segment is expected to accelerate through the 2026-2034 forecast period as precision oncology workflows become standard of care.

While oncology is the primary focus, nuclear medicine diagnostics are also gaining traction in cardiology. The ability of nuclear imaging to assess myocardial perfusion, evaluate cardiac function, and detect ischemic heart disease is driving its adoption in cardiology departments. SPECT and PET imaging provide valuable information about blood flow and tissue viability, which is essential for the diagnosis and management of cardiovascular diseases. The growing burden of cardiovascular diseases, particularly in aging populations, is expected to drive further growth in this segment. Additionally, ongoing research into the development of novel radiotracers for cardiac imaging is expanding the range of clinical applications and attracting new investment from major industry participants.

Neurology represents another important application area for nuclear medicine diagnostics. The use of PET and SPECT imaging in the evaluation of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and epilepsy, is increasing steadily. These modalities enable the assessment of brain function, neurotransmitter activity, and receptor binding, which are critical for the diagnosis and monitoring of neurological conditions. The rising prevalence of neurodegenerative diseases, coupled with the need for early and accurate diagnosis, is driving the adoption of nuclear medicine diagnostics in neurology. The development of specialized tracers targeting amyloid plaques and tau proteins is further expanding the utility of these technologies in neurological applications, with several such agents now holding regulatory approval in major markets as of 2025.

Thyroid imaging is another significant application of nuclear medicine diagnostics. The use of radiotracers to assess thyroid function, detect nodules, and differentiate between benign and malignant lesions is well established in clinical practice. Planar scintigraphy and SPECT imaging are commonly used for thyroid scans, providing valuable information for the management of thyroid disorders. The increasing incidence of thyroid cancer and other thyroid-related conditions is expected to drive steady demand for nuclear medicine diagnostics in this segment through 2034. Other applications, such as infection imaging and bone scans, also contribute to the overall growth of the market, with bone scintigraphy remaining particularly relevant for staging and monitoring skeletal metastases.

End User Analysis

The end user segment of the cancer nuclear medicine diagnostics market is divided into hospitals, diagnostic centers, academic and research institutes, and others. Hospitals represent the largest end user segment, accounting for a significant share of the market in 2025. The presence of advanced imaging infrastructure, skilled healthcare professionals, and the ability to handle complex diagnostic procedures make hospitals the primary setting for nuclear medicine diagnostics. The integration of nuclear medicine departments within hospitals allows for seamless coordination between diagnostic and therapeutic services, which is particularly important in the management of cancer patients. The increasing adoption of hybrid imaging systems and the availability of comprehensive cancer care facilities are further driving the demand for nuclear medicine diagnostics in hospitals.

Diagnostic centers are emerging as important and fast-growing end users of nuclear medicine diagnostics, particularly in urban areas with high patient volumes. These centers offer specialized imaging services, often equipped with the latest PET and SPECT systems, and cater to both outpatient and referral cases. The growing trend towards outpatient diagnostic services, driven by the need for convenience and cost-effectiveness, is contributing to the expansion of diagnostic centers. Furthermore, partnerships between diagnostic centers and healthcare providers are facilitating the wider adoption of nuclear medicine diagnostics, particularly in regions with limited access to hospital-based imaging facilities. The proliferation of dedicated oncology imaging centers is a notable trend shaping this end-user category in 2025.

Academic and research institutes play a crucial role in the advancement of nuclear medicine diagnostics. These institutions are at the forefront of research and development activities, focusing on the discovery of new radiopharmaceuticals, imaging techniques, and clinical applications. Academic centers often collaborate with pharmaceutical companies and medical device manufacturers to conduct clinical trials and validate the efficacy of novel diagnostic agents. The increasing emphasis on translational research and the integration of nuclear medicine into medical education are driving the adoption of these technologies in academic and research settings. Additionally, government funding and grants for cancer research are supporting the growth of nuclear medicine diagnostics in this segment through the 2026-2034 forecast period.

Other end users, such as specialty clinics and government healthcare facilities, also contribute to the overall demand for cancer nuclear medicine diagnostics. These settings often serve specific patient populations, such as those in rural or underserved areas, and play a vital role in expanding access to advanced diagnostic services. The implementation of mobile imaging units and telemedicine solutions is further enhancing the reach of nuclear medicine diagnostics, particularly in regions with limited healthcare infrastructure. Overall, the diverse range of end users highlights the widespread adoption and growing importance of nuclear medicine diagnostics in the global fight against cancer.

Opportunities & Threats

The cancer nuclear medicine diagnostics market is poised for significant growth, driven by a multitude of opportunities. One of the most promising opportunities lies in the ongoing advancements in radiopharmaceutical development. The discovery of new biomarkers and the synthesis of targeted radiotracers are expanding the range of cancers that can be effectively diagnosed using nuclear medicine. Additionally, the integration of artificial intelligence and machine learning algorithms into imaging analysis is enhancing diagnostic accuracy and efficiency, paving the way for personalized medicine approaches. The increasing adoption of hybrid imaging systems, such as PET/CT and SPECT/CT, is also opening up new avenues for comprehensive cancer assessment and treatment planning. The broader field of nuclear imaging is benefiting from these convergent technological trends, which are reshaping the standard of care in oncology across all major markets.

Another key opportunity is the expansion of nuclear medicine diagnostics in emerging markets. As healthcare infrastructure improves and awareness about the benefits of early cancer detection grows, there is a rising demand for advanced diagnostic services in countries across Asia Pacific, Latin America, and the Middle East and Africa. Governments and private sector stakeholders are investing in the establishment of nuclear medicine facilities and training programs, which is expected to drive market growth in these regions through 2034. Furthermore, collaborations between international organizations, healthcare providers, and research institutions are facilitating technology transfer and capacity building, enabling broader access to nuclear medicine diagnostics. The theranostics revolution, which pairs diagnostic radiopharmaceuticals with their therapeutic counterparts, is also creating substantial commercial opportunities for market participants during the forecast period.

Despite the numerous growth opportunities, the cancer nuclear medicine diagnostics market faces certain restraints. One of the primary challenges is the high cost associated with nuclear medicine procedures and equipment. The procurement and maintenance of advanced imaging systems, as well as the production and distribution of radiopharmaceuticals, require substantial investment. Additionally, stringent regulatory requirements for the approval and use of radiopharmaceuticals can delay the introduction of new products to the market. The complexity of radioisotope supply chains, including reliance on nuclear reactors and cyclotrons, introduces further vulnerability. Limited availability of trained professionals and specialized infrastructure in certain regions also poses a barrier to the widespread adoption of nuclear medicine diagnostics. Addressing these challenges will be critical to unlocking the full potential of this rapidly evolving market over the 2026-2034 forecast horizon.

Regional Outlook

North America continues to lead the global cancer nuclear medicine diagnostics market, with a market size of USD 3.19 billion in 2025. The region's dominance is attributed to its advanced healthcare infrastructure, high adoption rates of cutting-edge diagnostic technologies, and strong emphasis on cancer screening and early detection. The presence of leading pharmaceutical and medical device companies, along with robust research and development activities, further supports market growth in North America. The United States, in particular, accounts for a significant share of the regional market, driven by favorable reimbursement policies, a large patient population, and ongoing investment in healthcare innovation. Recent FDA approvals of PSMA-targeted PET tracers and lutetium-based theranostic pairs are reinforcing the region's leadership position heading into the forecast period.

Get Free Sample Report

Europe holds the second-largest share of the global cancer nuclear medicine diagnostics market, with a market size of USD 2.17 billion in 2025. The region benefits from well-established healthcare systems, government initiatives to promote cancer screening programs, and a strong focus on research and development. Countries such as Germany, France, and the United Kingdom are at the forefront of adopting advanced nuclear medicine technologies. The European market is expected to grow at a steady CAGR of 9.8% over the 2026-2034 forecast period, driven by increasing cancer incidence, rising healthcare expenditure, and ongoing efforts to improve access to diagnostic services.

The Asia Pacific region is emerging as the fastest-growing market for cancer nuclear medicine diagnostics, with a market size of USD 1.61 billion in 2025 and an anticipated CAGR of 12.4% from 2026 to 2034. The rapid growth in this region is fueled by increasing healthcare investments, rising awareness about cancer prevention and early detection, and expanding access to advanced diagnostic technologies. Countries such as China, India, Japan, and South Korea are leading the adoption of nuclear medicine diagnostics, supported by government initiatives and collaborations with international organizations. Latin America and the Middle East and Africa, with market sizes of approximately USD 0.35 billion and USD 0.22 billion respectively in 2025, are also witnessing gradual growth, primarily driven by improving healthcare infrastructure and increasing access to nuclear medicine services.

Competitor Outlook

The cancer nuclear medicine diagnostics market is characterized by intense competition and a dynamic landscape, with numerous global and regional players vying for market share. The competitive environment is driven by continuous innovation, strategic collaborations, and a focus on expanding product portfolios. Leading companies are investing heavily in research and development to introduce new and improved radiopharmaceuticals, imaging systems, and diagnostic solutions. The emphasis on personalized medicine and targeted diagnostics is prompting companies to develop agents that cater to specific cancer types and patient populations. Additionally, mergers and acquisitions, licensing agreements, and partnerships with research institutions are common strategies employed by market participants to strengthen their market position and enhance their technological capabilities.

The market is also witnessing increased collaboration between pharmaceutical companies, medical device manufacturers, and clinical networks. These partnerships are facilitating the translation of cutting-edge research into clinical practice, accelerating the development and commercialization of novel diagnostic agents. Regulatory approvals of new radiopharmaceuticals and imaging systems are further intensifying competition, as companies strive to differentiate their offerings through enhanced efficacy, safety, and patient outcomes. The entry of new players, particularly from the theranostics space and from emerging markets, is contributing to market dynamism and fostering innovation across the value chain heading into the 2026-2034 forecast period.

Key players in the cancer nuclear medicine diagnostics market are also focusing on expanding their geographic presence to tap into high-growth regions. Companies are establishing manufacturing facilities, distribution networks, and training centers in Asia Pacific, Latin America, and the Middle East and Africa to cater to the growing demand for nuclear medicine diagnostics. Additionally, investments in digital health solutions, such as artificial intelligence-based image analysis and remote diagnostics, are enabling companies to offer integrated and value-added services to healthcare providers and patients. The emphasis on sustainability and environmentally responsible manufacturing practices is also gaining traction, as companies seek to align with global regulatory expectations and investor priorities.

Among the major companies operating in the cancer nuclear medicine diagnostics market are GE Healthcare, Siemens Healthineers, Cardinal Health, Bracco Imaging S.p.A., Curium Pharma, Bayer AG, Lantheus Holdings, Inc., Advanced Accelerator Applications (a Novartis company), Jubilant Radiopharma, Nordion (Canada) Inc., Telix Pharmaceuticals Limited, Blue Earth Diagnostics, Eckert & Ziegler Group, SOFIE Biosciences, and NTP Radioisotopes SOC Ltd.. GE Healthcare and Siemens Healthineers are recognized for their comprehensive hybrid imaging solutions and global reach, while Cardinal Health and Curium Pharma are leading suppliers of radiopharmaceuticals across North America and Europe. Bracco Imaging and Bayer AG are renowned for their innovation in contrast agents and molecular imaging. Lantheus Holdings and Advanced Accelerator Applications are at the forefront of developing and commercializing targeted radiopharmaceuticals for cancer diagnostics and theranostic applications. Telix Pharmaceuticals is rapidly growing its PSMA-targeted diagnostic portfolio, while Jubilant Radiopharma and Nordion are notable contributors to radiopharmaceutical manufacturing and global isotope distribution.

These companies are actively engaged in product launches, regulatory approvals, and strategic collaborations to maintain their competitive edge through the 2026-2034 forecast period. GE Healthcare and Siemens Healthineers have introduced advanced digital PET/CT and SPECT/CT systems with AI-enhanced imaging capabilities, while Cardinal Health and Curium Pharma continue to expand their radiopharmaceutical portfolios through acquisitions and supply agreements. Bracco Imaging and Bayer AG are investing in the development of next-generation contrast agents and molecular imaging solutions. The collective efforts of these industry leaders are shaping the future of the cancer nuclear medicine diagnostics market, driving innovation, and improving patient care on a global scale.

Key Players

• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Canon Medical Systems Corporation
• Bracco Imaging S.p.A.
• Cardinal Health
• Curium Pharma
• Lantheus Holdings, Inc.
• Bayer AG
• Nordion (Canada) Inc.
• Advanced Accelerator Applications (Novartis AG)
• Eckert & Ziegler Group
• Telix Pharmaceuticals Limited
• Blue Earth Diagnostics (Bracco Imaging)
• Jubilant Radiopharma
• Isotopia Molecular Imaging Ltd.
• NTP Radioisotopes SOC Ltd.
• SOFIE Biosciences